The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre "Real-Life" Cohort Study.
Roberto CaporaliGiulia CataldiMartina GentileAlice DionisiPaola VolpeAnnacarla FinucciLucrezia VerardiClaudia Di MuzioNoemi ItalianoEleonora CellettiMyriam Di PentaIlenia Di ColaAlessandra MarrelliAlessia AlfonsiFrancesco Delle MonacheFrancesco CipolloneMarco GabiniPaola CiprianiPublished in: Rheumatology and therapy (2024)
The "real-life" 6-month effectiveness of guselkumab was shown in patients with PsA, mainly characterised by active long-standing disease, previously treated with bDMARDs, and with comorbidities. Furthermore, a good DRR of guselkumab was estimated in the cumulative 18 months of follow-up and appeared to be not influenced by long disease duration, comorbidities, obesity, and previous bDMARDs.